TRDA trades 178.3% below Wall Street's consensus target of $14.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TRDA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Entrada Therapeutics, Inc. (TRDA) has a Wall Street consensus price target of $14.00, based on estimates from 6 covering analysts. With the stock currently trading at $5.03, this represents a potential upside of +178.3%. The company has a market capitalization of $195M.
Analyst price targets range from a low of $11.00 to a high of $17.00, representing a 43% spread in expectations. The median target of $14.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, TRDA trades at a trailing P/E of -1.3x. Analysts expect EPS to grow -5.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ARWRArrowhead Pharmaceuticals, Inc. | $6.1B | $43.11 | $101.56 | +135.6% | Buy | — | 22 |
NTLAIntellia Therapeutics, Inc. | $1.1B | $9.77 | $20.71 | +112.0% | Buy | — | 39 |
BEAMBeam Therapeutics Inc. | $2.2B | $21.01 | $66.00 | +214.1% | Buy | — | 28 |
EDITEditas Medicine, Inc. | $272M | $1.77 | $5.50 | +210.7% | Buy | — | 26 |
CRSPCRISPR Therapeutics AG | $3.9B | $40.19 | $64.14 | +59.6% | Buy | — | 38 |
SRPTSarepta Therapeutics, Inc. | $1.5B | $14.53 | $21.00 | +44.5% | Buy | 4.7x | 55 |
RAREUltragenyx Pharmaceutical Inc. | $1.7B | $17.73 | $25.54 | +44.0% | Buy | — | 34 |
AGENAgenus Inc. | $267M | $6.40 | $25.00 | +290.6% | Buy | 23.9x | 12 |
IONSIonis Pharmaceuticals, Inc. | $4.6B | $27.39 | $84.92 | +210.0% | Buy | — | 33 |
LLYEli Lilly and Company | $1.3T | $1382.54 | $1445.12 | +4.5% | Buy | 39.1x | 46 |
Quick answers to the most common questions about buying TRDA stock.
The consensus Wall Street price target for TRDA is $14, representing 178.3% upside from the current price of $5.03. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TRDA has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $14 implies 178.3% upside from current levels.
TRDA's current price is $5.03 with a consensus target of $14 (178.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $17 for TRDA, while the most conservative target is $11. The consensus of $14 represents the median expectation. These targets typically reflect 12-month expectations.
TRDA is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TRDA stock forecast based on 6 Wall Street analysts shows a consensus price target of $14, with estimates ranging from $11 (bear case) to $17 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TRDA, with a "Buy" consensus rating and $14 price target (178.3% upside). 4 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TRDA analyst price targets range from $11 to $17, a 43% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $14 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.